ArticleIranian journal of microbiology2016
Immunoreactivity evaluation of a new recombinant chimeric protein against
Article in Iranian journal of microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
- Development of serologic diagnostic test based on in silico predicted synthetic peptides for Brucella canis in dogs.PloS one · 2026Article
- Immunization of mice with chimeric protein-loaded aluminum hydroxide and selenium nanoparticles induces reduction ofClinical and experimental vaccine research · 2023Article
- Immunogenicity of glycine nanoparticles containing a chimeric antigen asClinical and experimental vaccine research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesBrucellosis is an important health problem in developing countries and no vaccine is available for the prevention of infection in humans. Because of clinically infectious diseases and their economic consequences in human and animals, designing a proper vaccine against MATERIALS AND
methodsThree immunodominant antigens of
resultsSDS-PAGE and Western blotting results indicated the similarity of
conclusionThe recombinant chimeric protein could be a potential antigen candidate for the development of a subunit vaccine against
Indexed as
Identifiers
27928487PMC5139923W2494714848What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.